{"id":"bilastine-ophthalmic-solution-0-6","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dysgeusia (taste disturbance)"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":{"chemblId":"CHEMBL1742423","moleculeType":"Small molecule","molecularWeight":"463.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bilastine competitively antagonizes H1 histamine receptors on mast cells and other immune cells in ocular tissues, preventing histamine release and reducing allergic inflammation. When formulated as an ophthalmic solution, it provides local anti-allergic and antihistamine effects to relieve ocular allergy symptoms including itching, redness, and tearing.","oneSentence":"Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:34.502Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic conjunctivitis (ocular allergy symptoms)"}]},"trialDetails":[{"nctId":"NCT04810390","phase":"PHASE3","title":"Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2021-03-26","conditions":"Allergic Conjunctivitis","enrollment":59},{"nctId":"NCT03479307","phase":"PHASE3","title":"A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2018-04-07","conditions":"Allergic Conjunctivitis","enrollment":228},{"nctId":"NCT03231969","phase":"PHASE2","title":"A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2017-07-20","conditions":"Allergic Conjunctivitis","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bilastine Ophthalmic Solution 0.6%","genericName":"Bilastine Ophthalmic Solution 0.6%","companyName":"Faes Farma, S.A.","companyId":"faes-farma-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (ocular allergy symptoms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}